These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15919698)

  • 1. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus.
    Zaltzman JS; Prasad R; Chun K; Jothy S
    Nephrol Dial Transplant; 2005 Aug; 20(8):1748-51. PubMed ID: 15919698
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.
    Cullis B; D'Souza R; McCullagh P; Harries S; Nicholls A; Lee R; Bingham C
    Am J Kidney Dis; 2006 May; 47(5):e67-72. PubMed ID: 16632009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus.
    Mendelson M; Barday Z; Eastman R; Le Feuvre D; Candy S; Wu HT; Swanepoel C
    S Afr Med J; 2012 Aug; 102(12):924-6. PubMed ID: 23498038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.
    Boratyńska M; Smolska D
    Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
    Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL
    Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.
    Cutler C; Antin JH
    Bone Marrow Transplant; 2004 Sep; 34(6):471-6. PubMed ID: 15273708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of variability of sirolimus trough level on chronic allograft nephropathy.
    Wu MJ; Shu KH; Lian JD; Yang CR; Cheng CH; Chen CH
    Transplant Proc; 2008 Sep; 40(7):2202-5. PubMed ID: 18790192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
    Kaposztas Z; Etheridge WB; Kahan BD
    Transplant Proc; 2008 Jun; 40(5):1744-6. PubMed ID: 18589184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC; Warshaw BL
    Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclinical rejection and sirolimus associated edema in renal allograft recipients.
    Rico J; Cruzado JM; Bestard O; Duarte V; Rama I; Gomà M; Torras J; Grinyó JM
    Transpl Int; 2007 Jul; 20(7):636-9. PubMed ID: 17442067
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
    Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.